Daniel Tomaszewski, PharmD, Discusses How Practices in Managed Care Pharmacy Guided Legislation
Daniel Tomaszewski, PharmD, PhD Candidate, an assistant professor at the University of Minnesota, College of Pharmacy, Duluth, discusses the impact of managed care pharmacy on current legislation, regulatory policies, and ongoing healthcare reform.
This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 4, 2013.
Early this week, Novation, a healthcare services company that oversees supply chain management, called on Genentech to reverse its decision to use only specialty drug distributors instead of wholesale distributors for its widely used anticancer treatments, Avastin, Rituxan, and Herceptin.
The call for value-based care is propelled by the shortage of family physicians and the disparity connection between the time it takes to care for the sickest patients and what Medicare and Medicaid pay. A study in this month’s issue of The American Journal of Managed Care tracks just how bad things are, by looking at a normal day in a family practice.
Authors in the New England Journal of Medicine discuss the prospects and pitfalls of implementing a new CMS fee for physicians who coordinate care for Medicare patients with multiple chronic conditions.
Eric C. Schneider, MD, senior principal researcher and distinguished chair in health care quality at RAND, and director of its Boston office, will join The Commonwealth Fund as senior vice president for policy and research on February 2, 2015.
The ACO and Emerging Healthcare Delivery Coalition, an initiative of The American Journal of Managed Care, held its most recent WebEx session this week. Participants discussed new strategies and technologies that both employers and healthcare organizations can use to get patients to take ownership over their own care.
Amid last week's news that CMS had miscalculated the number of enrollees under the Affordable Care Act was a quieter announcement that the agency had appointed a chief data office to improve transparency, among other tasks.
Genentech's decision to use a handful of specialty drug distributors instead of wholesalers for the distribution of the most commonly used anticancer medications has raised concerns of availability and cost.